Chapman Financial Group LLC Takes $2.21 Million Position in Zoetis Inc. (NYSE:ZTS)

Chapman Financial Group LLC acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 13,190 shares of the company’s stock, valued at approximately $2,210,000. Zoetis makes up 1.8% of Chapman Financial Group LLC’s investment portfolio, making the stock its 11th largest position.

Several other large investors also recently made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC lifted its position in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC acquired a new stake in Zoetis during the 4th quarter valued at $30,000. Murphy & Mullick Capital Management Corp bought a new position in Zoetis during the fourth quarter worth $44,000. Finally, Asset Planning Inc bought a new position in shares of Zoetis in the fourth quarter valued at about $58,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 1.1 %

Shares of Zoetis stock opened at $157.43 on Monday. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $70.24 billion, a PE ratio of 28.78, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The firm’s 50 day moving average is $158.31 and its 200 day moving average is $167.05.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is currently 36.56%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 over the last 90 days. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ZTS. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Stifel Nicolaus cut their price target on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Finally, Piper Sandler upped their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $214.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.